File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Improved Detection of Antibodies against SARS-CoV-2 by Microsphere-Based Antibody Assay

TitleImproved Detection of Antibodies against SARS-CoV-2 by Microsphere-Based Antibody Assay
Authors
KeywordsCOVID-19
SARS-CoV-2
serology
flow cytometry
antibody assay
Issue Date2020
PublisherMolecular Diversity Preservation International. The Journal's web site is located at http://www.mdpi.org/ijms
Citation
International Journal of Molecular Sciences, 2020, v. 21 n. 18, p. article no. 6595 How to Cite?
AbstractCurrently available COVID-19 antibody tests using enzyme immunoassay (EIA) or immunochromatographic assay have variable sensitivity and specificity. Here, we developed and evaluated a novel microsphere-based antibody assay (MBA) for detecting immunoglobulin G (IgG) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleoprotein (NP) and spike protein receptor binding domain (RBD). The seropositive cutoff value was set using a cohort of 294 anonymous serum specimens collected in 2018. The specificity was assessed using serum specimens collected from organ donors or influenza patients before 2020. Seropositive rate was determined among COVID-19 patients. Time-to-seropositivity and signal-to-cutoff (S/CO) ratio were compared between MBA and EIA. MBA had a specificity of 100% (93/93; 95% confidence interval (CI), 96–100%) for anti-NP IgG, 98.9% (92/93; 95% CI 94.2–100%) for anti-RBD IgG. The MBA seropositive rate for convalescent COVID-19 patients was 89.8% (35/39) for anti-NP IgG and 79.5% (31/39) for anti-RBD IgG. The time-to-seropositivity was shorter with MBA than EIA. MBA could better differentiate between COVID-19 patients and negative controls with higher S/CO ratio for COVID-19 patients, lower S/CO ratio with negative controls and fewer specimens in the equivocal range. MBA is robust, simple and is suitable for clinical microbiology laboratory for the accurate determination of anti-SARS-CoV-2 antibodies for diagnosis, serosurveillance, and vaccine trials.
Persistent Identifierhttp://hdl.handle.net/10722/306716
ISSN
2023 Impact Factor: 4.9
2023 SCImago Journal Rankings: 1.179
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorFong, CHY-
dc.contributor.authorCai, JP-
dc.contributor.authorDissanayake, TK-
dc.contributor.authorChen, LL-
dc.contributor.authorChoi, CYK-
dc.contributor.authorWong, LH-
dc.contributor.authorNg, ACK-
dc.contributor.authorPang, PKP-
dc.contributor.authorHo, DTY-
dc.contributor.authorPoon, RWS-
dc.contributor.authorChung, TWH-
dc.contributor.authorSridhar, S-
dc.contributor.authorChan, KH-
dc.contributor.authorChan, JFW-
dc.contributor.authorHung, IFN-
dc.contributor.authorYuen, KY-
dc.contributor.authorTo, KKW-
dc.date.accessioned2021-10-22T07:38:35Z-
dc.date.available2021-10-22T07:38:35Z-
dc.date.issued2020-
dc.identifier.citationInternational Journal of Molecular Sciences, 2020, v. 21 n. 18, p. article no. 6595-
dc.identifier.issn1661-6596-
dc.identifier.urihttp://hdl.handle.net/10722/306716-
dc.description.abstractCurrently available COVID-19 antibody tests using enzyme immunoassay (EIA) or immunochromatographic assay have variable sensitivity and specificity. Here, we developed and evaluated a novel microsphere-based antibody assay (MBA) for detecting immunoglobulin G (IgG) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleoprotein (NP) and spike protein receptor binding domain (RBD). The seropositive cutoff value was set using a cohort of 294 anonymous serum specimens collected in 2018. The specificity was assessed using serum specimens collected from organ donors or influenza patients before 2020. Seropositive rate was determined among COVID-19 patients. Time-to-seropositivity and signal-to-cutoff (S/CO) ratio were compared between MBA and EIA. MBA had a specificity of 100% (93/93; 95% confidence interval (CI), 96–100%) for anti-NP IgG, 98.9% (92/93; 95% CI 94.2–100%) for anti-RBD IgG. The MBA seropositive rate for convalescent COVID-19 patients was 89.8% (35/39) for anti-NP IgG and 79.5% (31/39) for anti-RBD IgG. The time-to-seropositivity was shorter with MBA than EIA. MBA could better differentiate between COVID-19 patients and negative controls with higher S/CO ratio for COVID-19 patients, lower S/CO ratio with negative controls and fewer specimens in the equivocal range. MBA is robust, simple and is suitable for clinical microbiology laboratory for the accurate determination of anti-SARS-CoV-2 antibodies for diagnosis, serosurveillance, and vaccine trials.-
dc.languageeng-
dc.publisherMolecular Diversity Preservation International. The Journal's web site is located at http://www.mdpi.org/ijms-
dc.relation.ispartofInternational Journal of Molecular Sciences-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectCOVID-19-
dc.subjectSARS-CoV-2-
dc.subjectserology-
dc.subjectflow cytometry-
dc.subjectantibody assay-
dc.titleImproved Detection of Antibodies against SARS-CoV-2 by Microsphere-Based Antibody Assay-
dc.typeArticle-
dc.identifier.emailFong, CHY: chyfong@hku.hk-
dc.identifier.emailCai, JP: caijuice@hku.hk-
dc.identifier.emailChoi, CYK: yeekic@hku.hk-
dc.identifier.emailPang, PKP: pollpang@hku.hk-
dc.identifier.emailHo, DTY: tipyinho@hku.hk-
dc.identifier.emailPoon, RWS: rosana@hkucc.hku.hk-
dc.identifier.emailChung, TWH: tomwhc@HKUCC-COM.hku.hk-
dc.identifier.emailSridhar, S: sid8998@hku.hk-
dc.identifier.emailChan, KH: chankh2@hkucc.hku.hk-
dc.identifier.emailChan, JFW: jfwchan@hku.hk-
dc.identifier.emailHung, IFN: ivanhung@hkucc.hku.hk-
dc.identifier.emailYuen, KY: kyyuen@hkucc.hku.hk-
dc.identifier.emailTo, KKW: kelvinto@hku.hk-
dc.identifier.authoritySridhar, S=rp02249-
dc.identifier.authorityChan, KH=rp01921-
dc.identifier.authorityChan, JFW=rp01736-
dc.identifier.authorityHung, IFN=rp00508-
dc.identifier.authorityYuen, KY=rp00366-
dc.identifier.authorityTo, KKW=rp01384-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.3390/ijms21186595-
dc.identifier.pmid32916926-
dc.identifier.pmcidPMC7555114-
dc.identifier.scopuseid_2-s2.0-85090663691-
dc.identifier.hkuros328686-
dc.identifier.volume21-
dc.identifier.issue18-
dc.identifier.spagearticle no. 6595-
dc.identifier.epagearticle no. 6595-
dc.identifier.isiWOS:000581703100001-
dc.publisher.placeSwitzerland-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats